iFAST Diagnostics develops a test for antimicrobial susceptibility testing that reduces testing time from 48+ hours to 3-4 hours, providing results from blood or urine samples to help combat antimicrobial resistance.

iFAST Diagnostics

iFAST Diagnostics | 985 followers on LinkedIn. A Game-Changing, Low Cost, Rapid Antimicrobial Susceptibility Test - Ensuring The Right Antibiotic On Time, Every Time. | iFAST is developing a game-changing, rapid antimicrobial susceptibility test, that will enable every patient with bacterial infections to receive the right antibiotic, on time, every time.

Currently, these tests take 48-72 hours, but iFAST&#39;s tests are 10x faster - giving full quantitative and qualitative results in under 3 hours from a positive blood culture or bacterial isolate.

The technology is cheaper and involve less tedious manual labour than current standard of care, which is based on technology from the mid-1900s!

Non Executive Director | Chairman | COO | Finance, Operations & IT Director

Neil Bath

Dr Michael Hornsey, MRSB

Development Engineer at iFast Diagnostics

Kacper Wlodarczyk

IEng MIMechE, BEng (Hons). Mechanical Development Engineer at iFast Diagnostics

Oliver Matthews

A game-changing day for iFAST for two reasons - we have received Ethics Committee approval for our crucial UK clinical trial, to start in the New Year, and taken delivery of our first commercial design system! Everything on track for our big UK launch in Q2 2025.... watch this space for more exciting news on funding coming soon...

We are pleased to see that the WHO’s Director-General Dr Tedros Adhanom Ghebreyesushas specifically called for more rapid diagnostics technologies to help fight the scourge of AMR. This is exactly what iFAST will be bringing to the market next year – watch this space! https://lnkd.in/dsik5UPP

As the UN prepares to host the second High-Level Meeting on Antimicrobial Resistance (AMR) this week, highlighting the significance of this global health threat and the need to address solutions, iFast remains on track to launch in the UK in Q1 2025. Our game-changing innovation slashes the time needed to determine which antibiotics are effective, from 48 hours to just 3, without increasing test cost, thereby saving lives and reducing the spread of antimicrobial resistance. #medicaldiagnostics #innovation https://lnkd.in/e64smPvR

We are super-excited to announce the successful completion of our InnovateUK-funded Biomedical Catalyst project, in collaboration with UKHSA Porton Down and University of Southampton. The goals of the project included showing that we could extract Gram positive bacteria from positive blood cultures, and successfully perform our game-changing Antimicrobial Susceptibility test on them, all in under 3 hours. The project was delivered on time, on budget and met every deliverable and milestone, so massive thanks to everyone involved, especially Prof Mark Sutton, Lucy Bock and Rebecca Hodges from UKHSA, Prof Hywel Morgan and Katie Chamberlain from UoS and the whole team at iFAST. We can't wait for iFAST to be launched on the UK market in early 2025 - watch this space! Innovate UK ; University of Southampton ; Toby King

It would be true to say that people are dying every day because we are still using old-fashioned and slow methods to figure out which antibiotics will actually work - the process pictured (disk diffusion) takes two days but here at iFAST we have shown we can do the same thing at a similar cost in under 3 hours. Our test could help to save hundreds of thousands of lives per year. #medicaldiagnostics #medtech #medical #AMR #innovation #health https://lnkd.in/eA9FH-3j

We are delighted to report that iFast is recognised in the UK Government’s latest 5 year strategy for AMR. #innovation #medtech #medicaldiagnostics #AMR

A few days very successfully spent at ESCMID with the iFast team. Great to meet new connections and continue conversations. We're still here if you are. Do come and see us. #ESCMID #medicaltechnology #innovation

We're all ready at ESCMID Global 24 on Booth F52 and look forward to welcoming you onto the stand tomorrow. #medicaltechnology #innovation #medicalinnovation

Our latest video explains simply our groundbreaking antimicrobial susceptibility test, developed to ensure every patient with a bacterial infection receives the right antibiotic, on time, every time. We’ll be at ESCMID Global 24 on Booth F52 and hope to see you there. #medtech #innovation #medicaldiagnostics #medicaltechnology

Delighted that iFast has been selected to pitch to investors at the Rare Founders Demo Day and Conference on April 22nd in London. This conference day will give us the opportunity to share the value and importance of iFast and connect with fellow founders and investors. Date: Monday 22 April 2024 Time: 9am-5pm (conference) 6pm to 9pm (networking drinks) Location: 1 Wimpole Street, London W1G 0AE #rarefounders #futureofinvestment #medicaldiagnostics #medtech

Metric
Company Name	iFAST Diagnostics
Symbol
MSH ID	COM:IFASTDIAGNOSTICS
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Medical Diagnostics
Country	GB
Stage
Employee Count
Website	ifastdiagnostics.com
LinkedIn	ifast-diagnostics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

IFAS

COM:IFASTDIAGNOSTICS

iFAST Diagnostics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue